Back to results
US 10,669,320 B2Granted
Mps1 and KNL1 phosphorylation system
AssigneeThe Regents of the University of Michigan
InventorsAjit P. Joglekar, Pavithra Aravamudhan
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods for the treatment of cancer by activating the spindle assembly checkpoint (SAC) in cells. In particular, dimerized Mps1 and Spc105/KNL1 constructs are provided as tunable activators of SAC, allowing for control of chromosome segregation accuracy and prevention of aneuploidies that are common in cancer.
Claims4
A cellular or in vitro biochemical system comprising:
- (a) a kinase domain of the wild-type Mps1 (SEQ ID NO:2) linked to a first dimerization element;
- and
- (b) a phosphodomain of the wild-type KNL1 (SEQ ID NO:5) linked to a second dimerization element,
- wherein the kinase domain is capable of phosphorylating the phosphodomain, and
- wherein dimerization of the first dimerization element and second dimerization element facilitates phosphorylation of the KNL1 polypeptide by the Mps1 polypeptide.
2 more elements
Dependencies are inferred from the claim text.